Search Results 351-360 of 19719 for Receptor
Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer. J Clin Oncol. 2025 Jun; 43 (16):1875-1885 Epub 2025 Apr 11. View ...
Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-. Cancer. Researchers seek to improve success of chimeric antigen ...
T-cell receptor diversity may be key to treatment of follicular lymphoma, Mayo study. Cancer. T-cell receptor diversity may be key to treatment of ...
T-cell receptor diversity may be key to treatment of follicular lymphoma, Mayo study finds. Joe Dangor. February 19, 2019. Research finds ethnoracial ...
These treatments are sometimes called radiopharmaceutical therapy, nuclear medicine therapy, peptide receptor radionuclide therapy (PRRT), radioligand therapy ...
(open studies only). Filter this list of studies by location, status and more. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)- ...
Valsartan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes the blood vessels to tighten. As a result ...
Olmesartan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result ...
His research includes landmark work done on rare variants encoding the receptor target of inhaled bronchodilator therapy, the beta-2-adrenergic receptor gene.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.